Dan Zweifel

Dan Zweifel's work experience includes working as the Director of Clinical Pharmacology and Translational Medicine at Prothena Corporation plc since July 2022. Prior to that, they held the position of Senior Clinical Pharmacologist at Novartis starting in August 2021. From December 2017 to November 2021, they worked as a Clinical Specialist at Walgreens, where their responsibilities included conducting interventions, providing medical information, managing pharmacy operations, and counseling patients. Before that, they worked as a Staff member at Yale New Haven Hospital from November 2015 to November 2017. Dan also worked as a Research Scientist in Drug Development at Alexion Pharmaceutical from May 2012 to August 2014 and as a Project Management/Formulation Chemist/Consultant as a Consultant from January 2010 to January 2011. Their early experience includes working as a Bioanalytical Scientist in TOX/ADME at Eli Lilly and Company, Lilly Research Laboratories from March 2005 to January 2010, where they were responsible for developing and validating bioanalytical methods and managing a team.

Dan Zweifel's education history begins with obtaining a Bachelor of Science (BS) degree in Chemistry from Winthrop University. Dan then went on to pursue a Master's degree in Materials Science and Engineering at Clemson University. Following this, they obtained a Doctor of Medicine (MD) degree from Indiana University–Purdue University Indianapolis. Additionally, they pursued studies in chemical biology at Purdue University, and they hold a Doctor of Pharmacy (PharmD) degree with a specialization in Pharmacy, Pharmaceutical Sciences, and Administration from the University of Saint Joseph.